![](/img/cover-not-exists.png)
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
Röllig, Christoph, Serve, Hubert, Hüttmann, Andreas, Noppeney, Richard, Müller-Tidow, Carsten, Krug, Utz, Baldus, Claudia D, Brandts, Christian H, Kunzmann, Volker, Einsele, Hermann, Krämer, Alwin, ScLanguage:
english
Journal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(15)00362-9
Date:
November, 2015
File:
PDF, 373 KB
english, 2015